

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 2/7/1961  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**UroVysion FISH Final Report (Refer to test 2001181 UroVysion FISH)**

ARUP test code 8100610

UroVysion FISH Specimen Source: Urine

Clinical History: Clinical Information: No clinical information provided.

Gross Description: Received 75 mLs clear pale yellow urine in PreservCyt.

Fixative: PreservCyt

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**Interpretation**

Positive: Numeric chromosomal aberrations associated with urothelial carcinoma identified.

Positive results indicate the presence of one or more numeric chromosomal abnormalities commonly associated with urothelial carcinoma, within the cells collected in this specimen. Positive results in the absence of clinical documentation of urothelial carcinoma within the bladder suggest the possibility of urothelial carcinoma or other urologic malignancy from another site (including ureter, kidney, urethra and prostate). In this circumstance, further clinical evaluation to exclude these as a source of the abnormal cells is justified.

The vysis Urovysion Bladder Cancer Kit (Urovysion Kit) is approved for use by the U.S. Food and Drug Administration.

The Urovysion Bladder Cancer Kit (Urovysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the Urovysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

Appropriate controls are performed and worked correctly.

06/27/20 Reviewed by: Sandra B Larkin, CT(ASCP)

06/28/20 Verified By: Evelyn V Gopez, M.D.  
electronic signature

I certify that I personally conducted the evaluation on the above specimen(s) and have rendered the above interpretation(s).

University of Utah Health Care, Department of Pathology  
500 Chipeta Way  
Salt Lake City UT 84108

**Comments**

This test has been scanned by the Bioview automated slide screener and reviewed by the pathologist (CPT 88121).

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: UF-200-014895  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 3 | Printed: 11/24/2020 3:34:51 PM  
4848

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
UroVysion FISH Specimen Source	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM
Clinical History	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM
Gross Description	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM
Fixative	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM
Interpretation	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM
Comments	UF-200-014895	6/19/2020 11:22:00 AM	N/A	6/28/2020 12:49:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: